Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat added to standard quadruple therapy in heart failure with reduced ejection fraction
ChiCTR2500095278Phase 4Recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vericiguat in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Xijing Hospital. Primary endpoints: cardiovascular death and first hospitalization due to heart failure. Started Jan 2025; status: recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2500095278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095278.